Robert G L Shorr Net Worth

The estimated Net Worth of Robert G L Shorr is at least 188 千$ dollars as of 16 December 2015. Robert Shorr owns over 10,800 units of Brainstorm Cell Therapeutics stock worth over 7,952$ and over the last 19 years Robert sold BCLI stock worth over 180,480$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Robert Shorr BCLI stock SEC Form 4 insiders trading

Robert has made over 5 trades of the Brainstorm Cell Therapeutics stock since 2009, according to the Form 4 filled with the SEC. Most recently Robert sold 10,800 units of BCLI stock worth 29,268$ on 16 December 2015.

The largest trade Robert's ever made was selling 200,000 units of Brainstorm Cell Therapeutics stock on 4 October 2011 worth over 62,000$. On average, Robert trades about 25,388 units every 132 days since 2005. As of 16 December 2015 Robert still owns at least 28,399 units of Brainstorm Cell Therapeutics stock.

You can see the complete history of Robert Shorr stock trades at the bottom of the page.

What's Robert Shorr's mailing address?

Robert's mailing address filed with the SEC is 28 BROOKFALL ROAD, , EDISON,, NJ, 08817.

Insiders trading at Brainstorm Cell Therapeutics

Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over 1,899,994$ worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth 1,535,874$ . The most active insiders traders include Corp. Accbt、Mike Frankenberger、International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of 206,459$. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth 22,050$.

What does Brainstorm Cell Therapeutics do?

brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr

Complete history of Robert Shorr stock trades at Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics executives and stock owners

Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include:

• Chaim Lebovits,
  Chief Exec. Officer
• Chaim Lebovits,
  Chief Executive Officer
• Ralph Kern,
  President, Chief Medical Officer
• Dr. Ralph Z. Kern,
  Pres & Chief Medical Officer
• Dr. Stacy R. Lindborg Ph.D.,
  Exec. VP & Chief Devel. Officer
• Preetam Shah,
  Chief Financial Officer, Executive Vice President, Treasurer
• Irit Arbel,
  Vice Chairman of the Board
• Malcolm Taub,
  Independent Director
• Uri Yablonka,
  Executive Vice President, Chief Business Officer, Director
• June Almenoff,
  Independent Director
• Anthony Polverino,
  Independent Director
• Arturo Araya,
  Chief Commercial Officer
• Uri Yablonka,
  Exec. VP, Chief Bus. Officer, Sec. & Director
• Dr. Irit Arbel DSc, Ph.D.,
  Co-Founder & Independent Vice Chair of the Board
• Dr. Irit Arbel Ph.D., DSc,
  Co-Founder & Independent Vice Chair of the Board
• Sankesh Abbhi,
  Director
• Anthony Waclawski,
  Executive Vice President - Global Head of Regulatory Affairs
• Stacy Lindborg,
  Executive Vice President Head of Global Clinical Research
• David Setboun,
  Chief Operating Officer, Executive Vice President
• Jacob Frenkel,
  Chairman of the Board
• Antal Pearl-Lendner,
  VP & Chief Legal Counsel
• Alla Patlis CPA, M.B.A.,
  Controller & Interim CFO
• William K. White,
  Sr. VP & Head of Market Access and Pricing
• Dr. Daniel Offen,
  Chief Scientific Advisor
• Dr. Yael Gothelf,
  VP of Scientific & Regulatory Affairs
• Dr. David Setboun M.B.A., Pharm.D.,
  Exec. VP & COO
• Dr. Preetam Shah M.B.A., Ph.D.,
  Exec. VP, CFO & Treasurer
• Mordechai Friedman,
  Director
• International Holdings Ltd....,
  
• Alon Pinkas,
  Director
• Robert G L Shorr,
  Director
• Yoram Bibring,
  Chief Financial Officer
• Chen Schor,
  Director
• Eyal Rubin,
  CFO and Treasurer
• Nir Naor,
  Director
• Alla Patlis,
  See Remarks
• Anthony S. Fiorino,
  Chief Executive Officer
• Liat Sossover,
  Chief Financial Officer
• Avi Israeli,
  Director
• Adrian Harel,
  Acting Chief Executive Officer
• Corp. Accbt,
  10% owner
• Aviv University Economic Co...,
  10% owner
• Aviv University Tel,
  10% owner
• Abraham Efrati,
  Chief Executive Officer
• David Stolick,
  Chief Financial Officer
• At Tel Aviv University Ltd ...,
  10% owner
• Jonathan C Javitt,
  Director
• Beck Yaffa,
  President and CEO
• Moshe Lion,
  Director
• Michael D Greenfield,
  Director
• Yoram Drucker,
  Chief Operating Officer
• Mike Frankenberger,
  
• Kirk Taylor,
  Chief Medical Officer
• Hartoun Hartounian,
  EVP, Chief Operating Officer
• Ibrahim B. Dagher,
  Chief Medical Officer